OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI)
· seekingalpha.com
OmniAb (OABI) analysis: platform scaling via Eli Lilly partnership, milestone-rich revenue outlook, 2026 cash guidance, valuation and catalysts—read now.
Collaboration deals such as the one we just saw from Eli Lilly ( LLY ) would really make up the core investment case for OmniAb Inc. ( OABI ) here. In the sense...